Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will present a wide range of new breast cancer research at the 2025 San ...

Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.

Thomas Yau and colleagues’ CheckMate 9DW trial has yielded unprecedented results, with nivolumab plus ipilimumab reaching an overall response rate of 36%, a median progression-free survival of 9·1 ...

This important study describes a deep learning framework that analyzes single-cell RNA data to identify a tumor-agnostic gene signature associated with brain metastases. The identified signature ...

“This points more toward a model where the tumor is cleared and the T cells largely go away, Hinrichs noted in the interview. According to Hinrichs, this pattern was “sufficient for the long-term ...

When I was a kid, play just happened. There were backyards, rooftops, under mango trees and on the streets. Now, as a teacher in Dhaka and a mother of two, I see how much effort it takes to give kids ...

Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems for the acceleration of partners' clinical development, recently presented its Next-Generation LNP advancements, a ...

In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition of nivolumab (480 mg every 4 weeks). Patients with NSCLC will receive ...

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI)—designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National ...

A landmark Stanford Medicine study has shown that latent Epstein–Barr virus infection in B cells appears to drive almost all ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...